Standard biopsies blindly sample 1% of the prostate. We're here to set a new standard of care with MRI-targeted fusion biopsies.
Prostate cancer will affect 1 in 7 men. 1
The standards for screening and biopsy blindly sample the prostate without knowing where the cancer is, if any. We're here to set a new standard of care with MRI-targeted fusion biopsies.
Focal Healthcare is a world-class medical device company, dedicated to improving the physician and patient experience from prostate cancer diagnosis to treatment.
Standard biopsies blindly sample 1% of the prostate. We're here to set a new standard of care with MRI-targeted fusion biopsies.
Prostate cancer will affect 1 in 7 men. 1
The standards for screening and biopsy blindly sample the prostate without knowing where the cancer is, if any. We're here to set a new standard of care with MRI-targeted fusion biopsies.
Focal Healthcare is a world-class medical device company, dedicated to improving the physician and patient experience from prostate cancer diagnosis to treatment.
Standard biopsies blindly sample 1% of the prostate. We're here to set a new standard of care with MRI-targeted fusion biopsies.
Prostate cancer will affect 1 in 7 men. 1
The standards for screening and biopsy blindly sample the prostate without knowing where the cancer is, if any. We're here to set a new standard of care with MRI-targeted fusion biopsies.
Focal Healthcare is a world-class medical device company, dedicated to improving the physician and patient experience from prostate cancer diagnosis to treatment.
Working with a multi-disciplinary team of engineers, designers, developers, urologists, radiologists and patients we gain a diverse range of perspectives and turn those into meaningful insights. Taking the best of both worlds, we combine ultrasound with MRI and quality materials with user-centered design to create innovative imaging tools that simplify targeted biopsies and therapy.
Compared to ultrasound imaging, MRI can be considered the “Gold Standard” for detecting lesions. MRI-targeted biopsies with Fusion Bx lead to increased cancer detection rates by addressing 3 key sources of inaccuracy: prostate deformation, patient motion and registration.
Innovative technology doesn’t need to be complicated. Driven by end users, our 4-step guided workflow and semi-robotic arm eases the procedure for both physicians and patients.
Through rigorous testing and a fine attention to detail, we’ve developed a quality cost effective solution for fusion biopsies. Thoughtful engineering, multi- probe compatibility and accommodating customer service makes our system accurate, efficient and accessible to everyone.
Thoughtfully engineered, the Fusion Bx’s semi-robotic arm allows the probe to be maneuvered effortlessly, while maintaining consistent pressure on the prostate. With a freehand like motion and minimal prostate deformation, the Fusion Bx enables you to accurately locate and target suspicious regions of interest.
Fusion Bx strikes the optimal balance between accuracy and efficiency.
Learn more >
Fusion Bx provides meaningful and actionable results with less biopsies.
Learn more >
Email us for more information and we’ll start the conversation.
What causes prostate movement during a biopsy? Prostate movement can be extremely difficult to determine because it can deform and dislocate independently from surrounding structures
Focal Healthcare will be participating in the FOCAL (Frontiers in Oncologic Prostate Care and Ablative Local Therapy) course November 15th- 16th at the JW Marriott
Fusion Bx™ 2.0 MRI/Ultrasound fusion technology to provide targeted prostate biopsies across Europe TORONTO, CANADA – Focal Healthcare, an innovator of image-guided prostate cancer technology,
1 Statistics – Prostate Cancer Canada. (n.d.). Retrieved from prostatecancer.ca
2 Cookson, M. S., MD, & Stratton, K. L., MD. (2018, April 10). Point: Is MRI fusion biopsy the new gold standard for diagnosis?Urology Times. Retrieved from urologytimes.com